EcoDrugPlus

Integrin Subunit Beta 8

Ensembl ID : ENSATEG00000017924
Gene Symbol: ITGB8
3 Cross references
207 Possible Orthologues:

Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide)

Ensembl ID : ENSATEG00000024161
Gene Symbol: ITGA5
3 Cross references
206 Possible Orthologues:

Integrin, Alpha V

Ensembl ID : ENSATEG00000013370
Gene Symbol: ITGAV
2 Cross references
238 Possible Orthologues:

Integrin, Beta 1a

Ensembl ID : ENSATEG00000021926
Gene Symbol: ITGB1A
3 Cross references
209 Possible Orthologues:

Integrin, Beta 5

Ensembl ID : ENSATEG00000022714
Gene Symbol: ITGB5
3 Cross references
211 Possible Orthologues:

Interleukin-1 Receptor-Associated Kinase 4

Ensembl ID : ENSATEG00000018652
Gene Symbol: IRAK4
1 Cross references
202 Possible Orthologues:

Interleukin-8-Like

Ensembl ID : ENSATEG00000020661
Gene Symbol: LOC113161333
3 Cross references
177 Possible Orthologues:

Inward Rectifier Potassium Channel 2-Like

Ensembl ID : ENSATEG00000024142
Gene Symbol: LOC113162512
2 Cross references
197 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSATEG00000015169
Gene Symbol: IDH1
2 Cross references
234 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSATEG00000006165
Gene Symbol: IDH2
4 Cross references
196 Possible Orthologues:

Isotocin Receptor-Like

Ensembl ID : ENSATEG00000024633
Gene Symbol: LOC113153557
2 Cross references
186 Possible Orthologues:

Kappa-Type Opioid Receptor-Like

Ensembl ID : ENSATEG00000002927
Gene Symbol: LOC113164125
2 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).